SCHEMBL14949248

SCHEMBL14949248

CCOc1cc(Oc2ccc(-c3nnc(Nc4ccc(C)c(C)c4)[nH]3)cc2)nc(N)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.38
MAPT P10636 5/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
HPGD P15428 1/20 0.38
RAB9A P51151 5/20 0.38
NPC1 O15118 3/20 0.38
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
GAA P10253 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 3/20 0.36
DHODH Q02127 1/20 0.34
FFAR1 O14842 1/20 0.34
JAK2 O60674 2/20 0.34
NUDT1 P36639 1/20 0.34
TP53 P04637 3/20 0.33
POLB P06746 2/20 0.33
CYBB P04839 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14949246 0.91 SMN1; SMN2 (0.38) SMN1; SMN2MAPTMEN1KMT2AHPGD
SCHEMBL14949254 0.89 RAB9A (0.38) SMN1; SMN2MAPTMEN1KMT2AHPGD
SCHEMBL14949247 0.89 RAB9A (0.37) SMN1; SMN2MAPTMEN1KMT2ARAB9A
SCHEMBL12336247 0.88 PDGFRB (0.35) SMN1; SMN2MAPTMEN1KMT2AHPGD
SCHEMBL14949504 0.84 KDR (0.38) SMN1; SMN2MAPTRAB9ANPC1ALDH1A1
SCHEMBL14949265 0.84 NUDT1 (0.38) SMN1; SMN2MAPTMEN1KMT2AHPGD
SCHEMBL12336276 0.84 PDGFRB (0.49) MAPTALDH1A1KDM4EGAAHTT
SCHEMBL13547690 0.81 PDGFRB (0.36) SMN1; SMN2MAPTMEN1KMT2AHPGD
SCHEMBL14949331 0.80 RAB9A (0.39) SMN1; SMN2MAPTMEN1KMT2AHPGD
SCHEMBL14949693 0.80 PDGFRB (0.35) SMN1; SMN2MAPTGAACHEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8957216-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-02-17 US disclosed
US-8957216-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-02-17 US disclosed
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION AMITECH THERAPEUTIC SOLUTIONS INC (US) 2013-05-16 US disclosed
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION AMITECH THERAPEUTIC SOLUTIONS INC (US) 2013-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION MAP4K2, MAP3K20, MAP3K19 SMN1; SMN2 4181/4885MAPT 4114/4885MEN1 2954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.